3D Signatures Inc. Announces Positive Topline Results of Development Trial Assessing its Telo-HLTM Test for ...
(WorldNews Canada)

TORONTO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- 3D Signa­­­­­­tures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the `Company` or `3DS`) is pleased to announce that a preliminary third-party analysis of the trial data for Telo-HLTM, 3DS´ test in development for Hodgkin´s lymphoma (HL), shows that the Company´s TeloViewTM platform is able to distinguish, with a high degree of statistical significance, multiple differences between a patient group that responds to standard ABVD chemotherapy, and a group that relapses or is refractory to treatment within the first 12 months. ......